Pegvaliase (Palynziq)


 CADTH recommends that Palynziq should be reimbursed by public drug plans for the treatment of patients with phenylketonuria (PKU) aged 16 years and older who have inadequate blood phenylalanine control (blood levels greater than 600 µmol/L) on existing management if certain conditions are met.
 only covered to treat PKU older.
 demonstrate maintain a response less µmol/L), is prescribed clinician expertise in treating genetic metabolic disorders, cost reduced.